The FDA’s approval of SKYTROFA for adult GHD was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) clinical ...

New York City, NY, July 24, 2025 (GLOBE NEWSWIRE) -- Feedback from a recent survey shows that men and women who use ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low-dose somatropin and 11.1 cm/year with high-dose. In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm ...

Study participants born SGA were randomly assigned to receive somapacitan 0.24mg/kg/week, somatropin 0.035mg/kg/day (low dose), or somatropin 0.067mg/kg/day (high dose).

The FDA has approved a prefilled somatropin injection pen for the treatment of growth hormone disorders in adult and pediatric patients. It is expected to be available in the second quarter of 2010.